NetEase stock price target raised to $158 from $155 at Jefferies

TE Connectivity has maintained a 'Buy' rating on its stock at Jefferies, driven by anticipated growth in artificial intelligence (AI) and energy sectors. The positive sentiment reflects confidence in the company's ability to capitalize on these emerging markets, which are expected to drive significant revenue growth in the coming years.

NetEase reported mixed performance in its Q3 2025 earnings call, with shares falling by 3% after revenue missed analysts' expectations. The company continues to face challenges in maintaining its market position and financial stability, raising concerns among investors.

Veracyte presented its strategic expansion and growth plans at the Jefferies London conference. The company aims to enhance its market presence and operational efficiency in the healthcare sector. This initiative reflects Veracyte's commitment to leveraging new opportunities for future growth.

Jefferies has lowered its stock price target for ZTO Express to $25, reflecting a negative outlook on the market. This adjustment comes amid concerns regarding the company's financial performance and broader market conditions. Investors are reacting to these developments with caution as they assess the implications for ZTO Express's growth potential.

Kura Oncology received a Buy rating from Jefferies, highlighting its differentiated label. This positive sentiment reflects confidence in the company's strategic direction and product offerings. The rating is expected to influence investor interest and market performance.

NetEase shares fell by 3% after the company reported revenue that missed analysts' expectations. This decline reflects ongoing concerns about the company's financial performance and market position. Investors reacted negatively to the news, indicating a lack of confidence in NetEase's ability to meet future growth targets.

Valeo's stock has declined following a report from Jefferies, which indicated that the company's upcoming Capital Markets Day (CMD) targets are likely to disappoint investors. This negative sentiment reflects concerns about Valeo's future performance and market expectations.

Schrödinger announced a strategic shift towards a greater focus on research and development during its presentation at the Jefferies London conference. The company aims to enhance its capabilities in drug discovery and development, aligning its operations with evolving market demands.